Chronic NMDA receptor blockade or muscimol inhibition of cerebellar cortical neuronal activity alters the development of spinocerebellar afferent topography.
The requirement for cerebellar cortical neuronal activity in the development of spinocerebellar afferent topography was investigated in neonatal rats. In adult rats lower thoracic-upper lumbar spinocerebellar projections are localized to sharply circumscribed patches in the granule cell layer of the cerebellar anterior lobe. In transverse sections these patches appear as sagittally oriented stripes. This pattern develops postnatally as many spinal axons which initially project between the incipient stripes are eliminated thereby sharpening the stripe boundaries. We attempted to alter cerebellar cortical neuronal activity in neonatal animals to study the effects of these changes on the development of spinocerebellar stripes. In some experiments glutaminergic excitatory synaptic transmission was chronically blocked with the N-methyl-D-aspartate (NMDA) receptor antagonist 2-aminophosphovaleric acid (APV). In other experiments postsynaptic activity was directly inhibited by the gamma-aminobutyric acid agonist muscimol. Chronic exposure to APV or to muscimol did not affect the initial development of spinocerebellar projections; many spinal axons were present in the anterior lobe and arranged in incipient stripes. Both the APV and the muscimol appeared to prevent the elimination of interstripe projections; consequently the boundaries of the stripes remained poorly defined. These findings suggest that cerebellar cortical neuronal activity is a necessary requirement for the refinement of spinal afferent topography in the anterior lobe.
Tolbert
D L
DL
Francis and Doris Murphy Neuroanatomy Research Laboratory, Department of Anatomy and Neurobiology, MO 63104-1028.
Pittman
T
T
Alisky
J M
JM
Clark
B R
BR
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D001931:Brain Mapping; D002525:Cerebellar Cortex / Q000166:cytology* / Q000187:drug effects / Q000254:growth & development*; D006651:Histocytochemistry; D006735:Horseradish Peroxidase; D009118:Muscimol / Q000494:pharmacology*; D009411:Nerve Endings / Q000187:drug effects / Q000648:ultrastructure; D009412:Nerve Fibers / Q000187:drug effects / Q000648:ultrastructure; D009475:Neurons, Afferent / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013116:Spinal Cord / Q000166:cytology* / Q000187:drug effects / Q000254:growth & development*; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate; D014909:Wheat Germ Agglutinins
D016194:Receptors, N-Methyl-D-Aspartate; D018998:Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate; D014909:Wheat Germ Agglutinins; D009118:Muscimol; D015763:2-Amino-5-phosphonovalerate; D006735:Horseradish Peroxidase